Super‑compact treatment with a high dose of moxifloxacin in patients with drug‑resistant tuberculosis and its resistance mechanisms

Wang,Qingjiang; Zhang,Chunxiao; Guo,Jinhui; Huang,Jian; Xi,Xiue; Zhang,Ligong; Cui,Xiuqin

doi:10.3892/etm.2015.2230

April-2015 Volume 9 Issue 4

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

April-2015 Volume 9 Issue 4

Full Size Image

Article

Super‑compact treatment with a high dose of moxifloxacin in patients with drug‑resistant tuberculosis and its resistance mechanisms

Authors:
- Qingjiang Wang
- Chunxiao Zhang
- Jinhui Guo
- Jian Huang
- Xiue Xi
- Ligong Zhang
- Xiuqin Cui
View Affiliations / Copyright

Affiliations: Department of Tuberculosis, The First Affiliated Hospital of Xinxiang Medical University, Weihui, Henan 453100, P.R. China, Department of Pharmaceutics, The First Affiliated Hospital of Xinxiang Medical University, Weihui, Henan 453100, P.R. China
Pages: 1314-1318
|
Published online on: January 29, 2015

https://doi.org/10.3892/etm.2015.2230
Expand metrics +

Abstract

The aim of this study was to investigate the curative effect and resistance mechanisms of high‑dose moxifloxacin in the short‑term treatment of multidrug‑resistant tuberculosis. A total of 92 patients with multidrug‑resistant tuberculosis were randomly selected and divided into groups A and B (n=46 per group). The two groups received moxifloxacin treatment with the same dose in total. Group A received a short course of treatment with moxifloxacin (0.6 g/day for 6 months), whereas group B received normal moxifloxacin treatment (0.4 g/day for 9 months). Sputum negative conversion, foci absorption, cavity closure and adverse reactions in the two groups were observed, and the drug resistance mechanism of tuberculosis to moxifloxacin treatment was investigated. Following the treatment, the curative rate of group A was 82.61%, and the curative rate of group B was 84.78%; there was no statistically significant difference between the two groups (P>0.05). The rates of sputum negative conversion, foci absorption and cavity closure were not significantly different between the two groups (P>0.05). However, the rates of reduction in peripheral white blood cell counts, liver function damage and adverse reactions, including symptoms affecting the gastrointestinal and nervous systems, were significantly lower in group A than in group B (P<0.05). The expression levels of the antigen‑presenting functional molecules CD80 and CD40 on the surfaces of mononuclear cells were higher in group A than in group B (P<0.05), whereas the difference in HLA‑DR expression between groups A and B was not significant (P>0.05). In conclusion, short‑term treatment with a high dose of moxifloxacin is effective for multidrug‑resistant tuberculosis, and its advantages are a reduction in the incidence of drug‑associated adverse reactions and a lack of drug resistance.

View Figures

View References

1	Chen JL, Shi JW, Gu DL and Chen XL: The value of moxifloxacin and rifabutin strategy on super compact treatment of initial smear positive pulmonary tuberculosis. Chongqing Shi Yi. 41:2966–2968. 2012.(In Chinese).
2	Koh WJ, Lee SH, Kang YA, et al: Comparison of levofloxacin versus moxifloxacin for multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 188:858–864. 2013. View Article : Google Scholar : PubMed/NCBI
3	Chen WH, Xu B, Tang WQ, Zong XN, Luo PF, Cao S and Wei PM: Meta-analysis of refractory, recurrent and multi-drug resistant tuberculosis treatment by moxifloxacin. Nanjing Yi Ke Da Xue Xue Bao. 30:1166–1171. 2010.(In Chinese).
4	Jiang RH, Xu HB and Li L: Comparative roles of moxifloxacin and levofloxacin in the treatment of pulmonary multidrug-resistant tuberculosis: a retrospective study. Int J Antimicrob Agents. 42:36–41. 2013. View Article : Google Scholar : PubMed/NCBI
5	Chinese Medical Association. Guidance for Clinical Detection and Treatment (Tuberculosis). Beijing People’s Medical Publishing House; pp. 87–91. 2005
6	Manika K, Chatzika K, Zarogoulidis K and Kioumis I: Moxifloxacin in multidrug-resistant tuberculosis: is there any indication for therapeutic drug monitoring? Eur Respir J. 40:1051–1053. 2012. View Article : Google Scholar : PubMed/NCBI
7	Nosova EY, Bukatina AA, Isaeva YD, Makarova MV, Galkina KY and Moroz AM: Analysis of mutations in the gyrA and gyrB genes and their association with the resistance of Mycobacterium tuberculosis to levofloxacin, moxifloxacin and gatifloxacin. J Med Microbiol. 62:108–113. 2013. View Article : Google Scholar
8	Zvada SP, Denti P, Geldenhuys H, et al: Moxifloxacin population pharmacokinetics in patients with pulmonary tuberculosis and the effect of intermittent high-dose rifapentine. Antimicrob Agents Chemother. 56:4471–4473. 2012. View Article : Google Scholar : PubMed/NCBI
9	Berdot S, Papy E, Rioux C, et al: Use of moxifloxacin in tuberculosis regimen in a French teaching hospital. Med Mal Infect. 40:568–573. 2010.(In French). View Article : Google Scholar : PubMed/NCBI
10	Abbate E, Vescovo M, Natiello M, et al: Successful alternative treatment of extensively drug-resistant tuberculosis in Argentina with a combination of linezolid, moxifloxacin and thioridazine. J Antimicrob Chemother. 67:473–477. 2012. View Article : Google Scholar
11	Liu XY, Lin JX, Chen R and Peng DD: Clinical observation of super compact treatment of moxifloxacin in the initial treatment sputum positive pulmonary tuberculosis. Guangdong Yi Xue. 32:1749–1751. 2011.(In Chinese).
12	Fouad M and Gallagher JC: Moxifloxacin as an alternative or additive therapy for treatment of pulmonary tuberculosis. Ann Pharmacother. 45:1439–1444. 2011. View Article : Google Scholar : PubMed/NCBI
13	Pranger AD, van Altena R, Aarnoutse RE, et al: Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience. Eur Respir J. 38:888–894. 2011. View Article : Google Scholar : PubMed/NCBI
14	Balasubramanian V, Solapure S, Gaonkar S, et al: Effect of coadministration of moxifloxacin and rifampin on Mycobacterium tuberculosis in a murine aerosol infection model. Antimicrob Agents Chemother. 56:3054–3057. 2012. View Article : Google Scholar : PubMed/NCBI
15	Liang LL, Liu X and Ma Y: Effects of anti-tuberculosis containing with moxifloxacin or levofloxacin on multidrug resistant pulmonary tuberculosis. Zhongguo Yi Yuan Xie Hui. 14:1451–1453. 2011.(In Chinese).

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Super‑compact treatment with a high dose of moxifloxacin in patients with drug‑resistant tuberculosis and its resistance mechanisms

This article is mentioned in:

Abstract

Figure 1

Figure 2

Related Articles